论文信息 - Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. - 字舞流文

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

J. Schellens | E. Voest | H. Verheul | E. Brendel | M. Mergui-Roelvink | P. Witteveen | M. Langenberg | M. Lolkema | J. Krätzschmar | O. Christensen | B. Loembé | J. Roodhart | A. Nol-Boekel | J. Krätzschmar